Compare BEEP & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEP | ACRV |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | 76 |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 68.5M |
| IPO Year | 2021 | 2022 |
| Metric | BEEP | ACRV |
|---|---|---|
| Price | $1.74 | $1.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.50 | ★ $11.67 |
| AVG Volume (30 Days) | 96.1K | ★ 449.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,075,000.00 | N/A |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $22.12 | $568.17 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $1.20 |
| 52 Week High | $4.07 | $3.56 |
| Indicator | BEEP | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 41.17 |
| Support Level | $1.29 | $1.38 |
| Resistance Level | $2.33 | $2.15 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 39.08 | 2.70 |
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.